OptimizeRx Corp. (NASDAQ:OPRX) Given Average Recommendation of “Moderate Buy” by Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $13.4286.

Several analysts recently commented on OPRX shares. Stifel Nicolaus reduced their target price on OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. UBS Group set a $10.00 price objective on shares of OptimizeRx in a report on Wednesday, May 13th. Stephens reduced their price target on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 13th. B. Riley Financial lowered their price objective on OptimizeRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, Weiss Ratings lowered shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th.

Institutional Trading of OptimizeRx

A number of large investors have recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in shares of OptimizeRx in the second quarter valued at approximately $44,000. BNP Paribas Financial Markets lifted its stake in OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after purchasing an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in OptimizeRx during the 4th quarter valued at about $62,000. Aaron Wealth Advisors LLC purchased a new stake in shares of OptimizeRx during the first quarter valued at approximately $66,000. Finally, Hsbc Holdings PLC bought a new stake in OptimizeRx in the 1st quarter worth $85,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Stock Up 2.2%

Shares of OPRX opened at $6.55 on Tuesday. The company has a market capitalization of $122.88 million, a PE ratio of 18.71 and a beta of 1.08. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $22.25. The stock’s 50-day moving average price is $5.46 and its two-hundred day moving average price is $7.68. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%.The firm had revenue of $19.84 million for the quarter, compared to analyst estimates of $18.74 million. On average, analysts anticipate that OptimizeRx will post 0.51 EPS for the current year.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.